To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen»

S. Kozyreva; K. Kozyrev; S. Karsanov

doi:10.12737/5917

TO THE QUESTION OF COMPREHENSIVE TREATMENT IN THE PATIENTS WITH OVARIAN CANCER III-IV STAGES BY AUTOHEMOCHEMOTHERAPY ASSOCIATED WITH THE «MELAXEN» To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen»

АА Аа

Published in Journal of New Medical Technologies · Volume 21, Issue 3 · Pages 126–131 · Rubric: Clinical Picture and Methods of Treatment. Functional and Instrumental Diagnostics. New Medicinal Forms

DOI: https://doi.org/10.12737/5917

Received: 06.10.2014 Accepted: 06.10.2014 Published: 06.10.2014 Language of publication: RUS

Authors

S. Kozyreva

K. Kozyrev

S. Karsanov

S. Kozyreva

K. Kozyrev

S. Karsanov

ABSTRACT

This paper presents the positive characteristics of preoperative autohemochemotherapy associated with the drug "Melaxen” as a synthetic analogue of the epiphysial hormone melatonin, produced by Unipharm-USA in the complex treatment of patients with ovarian cancer on the stage III-IV. The authors emphasize that the "Melaxen" has a powerful antioxidant, anticarcinogenic and adaptogenic action, reduces stress response and regulates neuroendocrine function and biological rhythms. The authors believe that neoadjuvant autohemotherapy by the "Melaxen" with a powerful immunomodulatory and lipoic effects, improves general non-specific resistance of the organism, has a positive effect on the immediate and remote results of complex treatment of patients. In comparison with polychemotherapy, the autohemotherapy in combination with the “Melaxen" has the advantages. This therapy is significant in several basic methods of treatment of malignant tumors of the localization. It was found that with autohemochemotherapy by the "Melaxen" improves efficiency polychemotherapy, reduces its toxicity, consequently, clinically warranted and expedient in this connection, can be used as subsidiary means complex treatment of ovarian cancer recurrence in the spread process. The drug allows to improve the quality of life, to increase its duration in critically ill patients.

KEYWORDS

ovarian cancer, complex treatment, autohemochemotherapy, "Melaxen."

1. Anisimov V.N. Melatonin i ego mesto v sovremen-noy meditsine. Russkiy meditsinskiy zhurnal. 2006. N 4. S. 269-273.

2. Metodicheskie i organizatsionnye printsipy selektivnogo skrininga raka sheyki matki, tela matki i yaichnikov / Zalutskiy I.V. [i dr.]. Voprosy onkologii. 2006. T. 52. №1. S. 74 -77.

3. Kozyreva S.M. Autogemokhimioterapiya v kompleksnom lechenii raka sheyki matki II stadii: Avtoref. dis. … kand. med. nauk. Rostov n/D, 2009. 25 s.

4. Kozyreva S. M., Khetagurova L. G., Kozyrev K. M. Patofiziologicheskoe obosnovanie kompleksnogo primeneniya autogemokhimioterapii i adaptogennogo fitokokteylya «Bioritm-RS» dlya optimizatsii lecheniya raka sheyki matki. Pervyy Rossiyskiy s´´ezd po khronobiologii i khronomeditsine s mezhdunarodnym uchastiem. Vladikavkaz. URAN IBMI VNTs, 2008. S.163-166.

5. Kozyreva S. M., Sidorenko Yu.S., Khetagurova L.G., Kozyrev K.M. Patofiziologicheskaya otsenka effektivnosti kompleksnogo primeneniya autogemokhimioterapii i khronomeditsinskikh sposobov lecheniya raka sheyki matki. VII s´´ezd onkologov Rossii. Sbornik materialov. M., 2009. T.II. S. 55-56.

6. Kozyreva S.M., Sidorenko Yu.S., Kozyrev K.M. Primenenie novykh meditsinskikh tekhnologiy v kompleks-nom lechenii raka sheyki matki. Vestnik novykh meditsinskikh tekhnologiy. 2010. T.17. № 1. S. 63-67.

7. Kozyreva S. M., Sidorenko Yu.S., Kozyrev K.M. Blizhayshie rezul´taty lecheniya bol´nykh rakom sheyki matki IIB stadii s primeneniem autogemokhimioterapii. Vladikavkazskiy mediko-biologicheskiy vestnik. 2009. 2010. T.9. S.63-68.

8. Kozyreva S. M., Gatagonova T.M., Khetagurova L.G., Kozyrev K.M. (Monografiya). Kliniko-morfologicheskaya otsenka lecheniya raka sheyki matki autogemokhimioterapiey. Vliyanie fitoadaptogenov. Vladikavkaz, 2010. 180 s.

9. Kozyreva S.M., Kozyrev K.M. Rezul´taty kom-pleksnogo lecheniya bol´nykh rakom yaichnikov s primeneni-em autogemokhimioterapii. Vestnik novykh meditsinskikh tekhnologiy. 2012. T. 19. №1. S. 68-71.

10. Merdenova L.A., Sozaeva Z.Yu., Khetagurova L.G. Melatonin - mezhkletochnyy neyroendokrinnyy regulyator zhiznedeyatel´nosti organizma. Vladikavkazskiy mediko-biologicheskiy vestnik. 2008-2009. T. 8. №14. S.34-40.

11. Sidorenko Yu.S. Autogemokhimioterapiya. - Rostov n/D, 2002. 303 s.

12. Tyulyandin S.A. Lechenie bol´nykh rasprostranen-nym rakom yaichnikov. V ezhegodnaya Rossiyskaya onkologicheskaya konferentsiya. M., 2001. S.18-20.

13. Melatonin as antioxidant, geroprotector and anticarcinogen / Anisimov V.N., Popovich I.G., Zabezhinski M.A. [et al.] . Biochim. Biophys. Acta - Bioenergetics. 2006. Vol. 1757. № 5-6. P. 573-589.

14. Arendt J. Melatonin: Characteristics, concerns, and prospects. J. Biol. Rhytms. 2005. Vol. 20. №4. P. 291-303.

15. Karsliogly I., Ertekin M.V, Taysi S. Radioprotective effects of melatonin on radiation-induced cata¬ract. J. Radiat.Res. 2005. Vol. 46. №2. P.277-282.

16. Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Department of Gynecology and O bstetrics, Hôpital Tenon, Paris, France / Piketty M. [et al.]// Am J. Obstet Gynecol. 2007, Feb;196(2):e22.

17. Volante R., Ronco G. National survey of the quality of 2nd level in screening for cervical cancer. Azienda Ospedaliera O.I.R.M. Sant´Anna, Torino: Epidemiol Prev. 2006. №1. P. 51-57.

JATS XML

Editor-in-Chief, editorial board chair

GOST

Kozyreva S., Kozyrev K., Karsanov S. To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen» // Journal of New Medical Technologies. 2014. no. 3. pp. 126-131. DOI: https://doi.org/10.12737/5917. (Date of access 01.10.2026).

MLA

S. Kozyreva, Kozyrev K., Karsanov S.. "To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen»." Journal of New Medical Technologies 21.3 (2014): 126-131. DOI: https://doi.org/10.12737/5917.

APA

Kozyreva S., Kozyrev K., Karsanov S. (2014). To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen». Journal of New Medical Technologies, 21(3), 126-131. https://doi.org/10.12737/5917

Chicago

S. Kozyreva, Kozyrev K., Karsanov S.. "To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen»." Journal of New Medical Technologies 21, no. 3 (2014): 126-131. https://doi.org/10.12737/5917.

WIKI

{{cite journal | author = Kozyreva S., Kozyrev K., Karsanov S. | title = To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen» | journal = Journal of New Medical Technologies | year = 2014 | volume = 21 | issue = 3 | pages = 126-131 | doi = 10.12737/5917 }}

Copy

Export: BibTeX EndNote RefMan RusMARC

TO THE QUESTION OF COMPREHENSIVE TREATMENT IN THE PATIENTS WITH OVARIAN CANCER III-IV STAGES BY AUTOHEMOCHEMOTHERAPY ASSOCIATED WITH THE «MELAXEN» To the Question of Comprehensive Treatment in the Patients with Ovarian Cancer III-IV Stages by Autohemochemotherapy Associated with the «Melaxen»

Confirmation